Medical imaging AI funding tracker (100+ deals)

Our funding tracker covering the medical imaging AI market

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our medical imaging AI market report.

Is medical imaging AI really attracting billions in funding?

Yes, medical imaging AI startups raised at least $2.8B across 172 funding deals involving 131 companies in our coverage window.

We counted software that reads, measures, improves or helps clinicians use medical images. That includes CT, MRI, ultrasound, dental X-rays and pathology slides, but excludes healthcare AI without an imaging product. Amounts were public for 159 deals, representing 92% of the total. Undisclosed rounds remain in the count, which is why our capital figure is a minimum.

The FDA's register of AI-enabled devices now includes products from Aidoc, Subtle Medical and AZmed. Authorization does not tell us whether a company is profitable, but it confirms that these products have progressed beyond research demonstrations to defined clinical uses. Funding therefore covers businesses at very different points between model development and actual use in hospitals.

How big is a typical medical imaging AI funding round?

The median disclosed medical imaging AI round is $9.3M, far smaller than the deals that attract the biggest headlines.

The $5M to under $20M range accounted for 65 deals, or 41% of disclosed rounds, and at least $688M. Another 50 deals, or 31%, were smaller and raised at least $110M. These smaller checks can help startups test products clinically, secure clearances and win initial customers.

New Lantern's $19M Series A in November 2024 backed a radiology workspace. CARPL.ai raised $10M in a July 2026 Series A for imaging-AI infrastructure, while TileBio's ~$2.1M Seed round in March 2026 funded work on pathology image models. Their products are different, but each financing sits much closer to an ordinary imaging AI round than a nine-figure announcement.

Are $100M medical imaging AI rounds becoming normal?

No, nine-figure medical imaging AI rounds remain rare: 5 disclosed deals, or 3% of rounds with a public amount, raised $578M.

The group includes Aidoc's $150M Series D+ in April 2026 and $110M Series D+ in July 2025, Harrison.ai's $112M Series C in February 2025, Cleerly's $106M Series C in December 2024 and DentalMonitoring's $100M Growth Equity round in February 2026. Investors plainly will finance big expansions, but a startup cannot treat checks of this size as normal.

The companies were paying for different ambitions. Harrison.ai has built products for radiology and pathology. Cleerly entered its funding round with Medicare coverage for its coronary plaque analysis. The large checks generally follow long product-development and clinical-sales efforts. One financing headline tells us little about how much a newly founded imaging AI company could raise. Laza Medical's November 2026 Series B, announced as structured financing of up to $160M, is not in this group: no committed amount was published, so we count it as a deal of undisclosed size.

Is Aidoc taking most of the medical imaging AI funding?

No, Aidoc leads the medical imaging AI companies we track with $260M raised across 2 rounds, but the market funds many other kinds of products.

Rad AI attracted $118M across 3 rounds, Harrison.ai raised $112M in 1 round, and Cleerly was also among the largest recipients. Their products do different jobs: Aidoc helps medical teams identify urgent imaging findings, Rad AI helps radiologists report exams, Harrison.ai analyzes clinical scans, and Cleerly measures disease in coronary CT images. These are sums raised during our coverage period, not valuations or lifetime funding.

Aidoc's recent financing backs its clinical foundation model and hospital software. Sirona Medical, by contrast, is building a radiology workspace that brings diagnostic viewing, worklists and reporting together. Large investors are backing several routes into daily clinical work. That leaves room for competing products even when one company tops the funding totals.

Do most medical imaging AI rounds happen at Seed?

Seed accounts for the most medical imaging AI deals, but later stages receive most of the disclosed capital.

We counted 55 Seed deals, or 32% of all deals, raising at least $193M. Series A recorded 42 deals and at least $570M. Among rounds with a named stage, early-stage financing accounted for 63% of deals but 29% of disclosed capital; later-stage deals received 71% of that money. The industry keeps funding new products while committing larger sums after companies have more to show.

Subtle Medical's $33M Series C in June 2026 backed image enhancement for MRI, PET and CT. Aidoc's later funding followed years of clinical product development, while younger radiology workflow startups were still building their initial products. These are different steps on the way from a first workable model to software hospitals use regularly.

The table below shows medical imaging AI financing by stage, ranked by disclosed capital.

Stage	Deals	Capital	Median
Series C	19	$641M+	$25M
Series D+	10	$591M	$48M
Series A	42	$570M+	$12M
Series B	20	$463M+	$23M
Seed	55	$193M+	$2.8M
Growth Equity	7	$183M+	$16M
Unknown	19	$127M+	$7.9M

A plus sign means at least that much disclosed funding; some round amounts were not published.

Can medical imaging AI startups still raise money after Series B?

Yes, medical imaging AI companies continue to raise substantial rounds after Series B, especially when they can show a path to routine clinical use.

Series C accounted for 19 deals involving 16 companies and at least $641M. Series D+ recorded 10 deals involving 8 companies and $591M. Growth Equity added 7 deals involving 6 companies and at least $183M. Those checks can fund larger sales teams, regulatory work and deployment across hospital networks, although a round label does not tell us exactly where the proceeds went.

Cleerly had won Medicare coverage for coronary plaque analysis before taking expansion funding. Harrison.ai was already selling diagnostic imaging technology across specialties. Sirona Medical's $40M Series D+ in October 2026 came after the company signed contracts covering substantial clinical imaging volume. Investors clearly remain interested after the early testing phase, provided the product can find paying users.

Does software that diagnoses images still get the most funding?

Yes, detection and diagnostic AI leads medical imaging AI funding with 80 deals, 47% of all deals, and at least $1.1B raised.

This covers software that finds disease or other clinically useful signs in images. Qure.ai's $65M Series D+ in September 2024 supported expansion of its imaging products, while Harrison.ai's large later-stage round backed radiology and pathology tools. Dental X-ray analysis is part of the opportunity too. Diagnostic AI now reaches well beyond standard radiology scans.

Still, other work gets funded. Imaging Workflow & Reporting brought in at least $435M through 24 deals, while Quantification & Measurement recorded $431M in 21 deals. Those products help clinicians organize exams, produce reports or quantify findings before treatment. We classify each startup by its main product, even when it also has other image-AI features.

The table below shows the medical imaging AI product categories by disclosed funding.

Category	Deals	Capital	Median
Detection & Diagnostic AI	80	$1.1B+	$8.6M
Imaging Workflow & Reporting	24	$435M+	$10M
Quantification & Measurement	21	$431M	$7.8M
Triage & Prioritization	7	$291M+	$12M
Image Reconstruction & Enhancement	12	$168M	$8.1M
Segmentation & Procedure Planning	15	$141M+	$11M
Acquisition & Quality Optimization	8	$98M+	$11M
Digital Pathology AI	4	$54M	$14M
Imaging AI Platforms	1	$32M	–

Categories reflect the primary product of each startup; a plus sign marks a minimum.

Are medical imaging AI investors funding more than scan detection?

Yes, medical imaging AI investors are funding reporting tools, measurement software and hospital workflows alongside products that spot abnormalities.

A radiologist may need a single place to see images, compare prior exams and complete a report. A cardiologist may need consistent plaque measurements before deciding on treatment. Both jobs create a reason to buy AI software without asking it to make every diagnosis.

New Lantern's $19M Series A in November 2024 focused on radiology viewing and reporting. Incepto Medical's $16M Growth Equity round in September 2026 backed software for bringing multiple imaging algorithms into clinical practice. Cleerly, meanwhile, has used reimbursement coverage to make coronary CT measurements easier to offer as a clinical service. Investors are backing the jobs hospitals already have to perform, including the less glamorous ones.

Is medical imaging triage AI mostly Aidoc now?

Aidoc accounts for much of the funding scale in medical imaging triage AI, although other companies continue working on the same clinical problem.

Triage & Prioritization recorded 7 deals involving 5 companies and at least $291M of disclosed capital. Aidoc's financings during our coverage window made it the category's most prominent funded business. Its software identifies urgent imaging findings and helps notify the people who need to act, so the product extends beyond image detection.

Aidoc also received FDA Breakthrough Device Designation for its investigational First Read chest X-ray reporting product in June 2026. The designation does not authorize the product for marketing; the company's already cleared triage tools appear separately in FDA records. The distinction shows how Aidoc is widening its clinical work, while leaving room for smaller competitors focused on individual findings or care pathways.

Can medical imaging AI raise money without making diagnoses?

Yes, medical imaging AI that improves scans or guides clinicians during acquisition has attracted substantial funding without replacing the final diagnosis.

Image Reconstruction & Enhancement drew 12 deals involving 10 companies and $168M of funding. Acquisition & Quality Optimization accounted for 8 deals involving 6 companies and at least $98M, a minimum because Laza Medical's Series B has no committed amount. Hospitals have immediate reasons to reduce repeat scans, work faster and help more clinicians capture usable images.

Subtle Medical's $33M Series C in June 2026 supported enhancement of existing MRI, PET and CT scans. AIRS Medical raised $22M in a September 2026 Series D+ for MRI reconstruction, and UltraSight's $24M Series B that month financed AI-guided cardiac ultrasound. Rather than competing over who diagnoses a scan, these companies work on what happens before a clinician can read it.

Are heart-scan startups raising some of the biggest imaging AI rounds?

Yes, cardiac medical imaging AI has attracted some of the largest individual rounds, led by Cleerly's $106M Series C, especially for products used during procedures or treatment decisions.

Cleerly's $106M Series C in December 2024 supported coronary CT plaque analysis. Laza Medical's Series B in November 2026, announced as up to $160M of structured financing, backed intelligent imaging for catheterization laboratories, but its committed amount is not published. Elucid raised $55M in a September 2026 Series D+ for image-derived cardiovascular measurements, while UltraSight's financing that month supported guided echocardiography. The companies are tackling different steps in heart care, so their technologies should not be treated as substitutes.

We do not publish a separate cardiac funding total, because cardiac products appear in different primary categories. What links these examples is a specific clinical use: getting a better image, measuring a risk or guiding a procedure. Cleerly's insurance coverage illustrates the next challenge. A product becomes much easier to sell when clinicians have a clear way to be paid for using it.

Is dental imaging AI getting serious funding now?

Yes, dental imaging AI is now attracting substantial rounds because dentists can use image analysis in exams they perform every day.

Overjet raised $53M in a March 2024 Series C, Videa raised $40M in a January 2025 Series B, and DentalMonitoring secured $100M in a February 2026 Growth Equity round. Overjet analyzes dental radiographs, Videa combines image analysis with clinical and practice workflows, and DentalMonitoring uses patient images to support orthodontic monitoring.

Overjet named March Capital as lead in its financing; Videa named Threshold Ventures and pointed to its expansion among dental service organizations. Dental clinics buy software differently from large radiology departments, with different workflows and buying decisions. Dental financing sits inside our broader market categories, but these rounds show that the field can support companies aimed specifically at dental care.

Is pathology AI still too small for big investors?

Only partly: digital pathology AI is a small named category in medical imaging AI, yet several well-funded pathology companies sit in other categories.

The dedicated category recorded 4 deals involving 4 companies and $54M. Proscia's $50M Growth Equity round in March 2025 belongs to Imaging Workflow & Reporting because it sells pathology software used by laboratories. AIgnostics' $34M Series B in October 2024 belongs to Detection & Diagnostic AI. TileBio's early financing supports models trained on tissue images.

Proscia builds tools for managing and analyzing digital slides; AIgnostics works on pathology image analysis; newer teams develop models that can support multiple downstream uses. Mayo Clinic's work with AIgnostics and NVIDIA also shows how clinical institutions are contributing images and expertise. A label covering only dedicated pathology AI understates the number of ways investors can finance this work.

Are most funded medical imaging AI startups new companies?

Not exactly, because many funded medical imaging AI startups had spent years developing their products before raising new money.

Among companies we tracked, 87% were founded since 2015, 44% since 2020 and 25% since 2022. These are shares of companies, not shares of deals or money. The current enthusiasm for AI did not create the entire field overnight.

Qure.ai was founded in 2016 and developed clinical imaging products well before the current generative-AI boom. Cleerly spent years on coronary CT analysis and reimbursement before raising its major expansion round. Newer companies such as TileBio are still exploring tissue-image models. Clinical studies, regulatory reviews and hospital sales can take years, which helps explain why older startups attract larger rounds.

Do imaging AI startups need years to raise big rounds?

Usually, the median age of medical imaging AI companies raising rounds above $50M was 8 years, compared with 4 years for rounds under $5M.

Across funded companies, the median age at financing was 6 years. That does not mean investors reward a company's birthday. Older startups have simply had more time to test products, work through authorization and build contracts with hospitals or insurers.

Qure.ai's later-stage financing followed a long period of international clinical work. Sirona Medical's expansion round came after its radiology software had won contracted volume across multiple facilities. A young pathology-model startup faces a different set of questions about validation and distribution. The data does not prove that age causes larger rounds, but it shows why the fastest route to a clinical product often takes years.

Can a new medical imaging AI startup still raise its first round?

Yes, new medical imaging AI startups still raise first rounds, although established companies receive most of the disclosed money.

We found 34 first financings involving 34 companies, representing 20% of the deals and at least $215M. Follow-ons accounted for 98 deals involving 75 companies and at least $2.2B. The median first financing was $3.7M, against $15M for a follow-on. Another 40 deals have no known status, because we call a round a follow-on only when an earlier equity round is in our data and a first financing only when the source says so. New products still attract backing, but investors reserve larger checks for companies returning with additional evidence.

Octopath AI raised ~$1.3M at Seed in November 2026 for pathology image analysis. New Lantern's $19M Series A in November 2024 is the first round we found for the company, so a first round can also be substantial. Here, "first" means the first qualifying financing we identified, rather than a claim that the founders never received any other support.

How long do medical imaging AI startups wait between rounds?

The median gap between observed medical imaging AI financing rounds was 23 months, so a follow-on within a year is relatively fast.

Among round-to-round intervals with sufficient date coverage, 27% were under 12 months and 51% were under 24 months. Those figures describe intervals, not shares of startups. Across our coverage window, 34 companies, or 26% of the funded companies, had multiple qualifying rounds.

Rad AI's $50M Series B in May 2024 was followed by a $60M Series C in January 2025 and an $8M extension of that Series C in May 2025. Sirona Medical completed later-stage rounds at a longer interval, while Brainomix returned for an extension to its Series C. The examples show that repeat funding may mean a new stage or an addition to an existing round; neither automatically proves sales growth.

Is Europe getting more medical imaging AI funding than North America?

Europe recorded more medical imaging AI deals, but North America received more disclosed money.

Europe accounted for 75 deals, or 44%, involving 60 companies and at least $767M. North America recorded 57 deals, or 33%, involving 43 companies and at least $1.1B. We locate startups by headquarters, so these figures do not describe where the investors live or the hospitals that use each product.

France recorded 20 deals and at least $271M, while the United Kingdom had 19 deals and at least $178M. The United States recorded 52 deals and at least $1.1B. Europe's strength is the number of funded companies and transactions. North America has attracted larger individual checks, helped by later-stage developers working on radiology workflows and cardiovascular imaging.

Does Israel's imaging AI funding depend on a few big rounds?

Yes, Israel's medical imaging AI funding is strongly shaped by a small group of established companies, especially Aidoc.

We counted 7 Israeli deals involving 5 companies and $372M in disclosed funding. Aidoc's large later-stage rounds are a major part of that picture. UltraSight raised $24M in a September 2026 Series B to expand its AI-guided cardiac ultrasound work. These products solve different problems, but both have clear ties to clinical workflows in US healthcare.

Aidoc is developing software to detect significant imaging findings and support follow-up decisions, while UltraSight helps clinicians acquire interpretable ultrasound images. The dollar total makes Israel look particularly large compared with its deal count. It would be a mistake to assume that every Israeli medical imaging startup can raise the kinds of checks announced by its best-known companies.

Does medical imaging AI funding come steadily or in bursts?

Medical imaging AI startups raise money in every completed month of our coverage, but the biggest dollar totals come in bursts.

Across 34 completed months, the median month had 5 deals and $55M, and no month was without a deal. July 2024 was busiest by count, with 9 deals. January 2025 led by money, with $265M, helped by Deepwise. A month with fewer deals can easily attract more money if one company raises a large round.

April 2026 recorded 7 deals and $213M, including a large Aidoc financing. July 2026 recorded 1 deal. November 2026 is still a partial month, with 2 deals and at least $1.3M, since Laza Medical's Series B has no committed amount. We should read these as bursts of announced funding, not as a smooth monthly acceleration or decline.

The table below shows selected months from the complete coverage period in chronological order.

Month	Deals	Capital
January 2024	2	$20M
July 2024	9	$174M
December 2024	4	$126M+
January 2025	8	$265M
July 2025	6	$207M
December 2025	4	$38M
April 2026	7	$213M
July 2026	1	$10M
November 2026 (partial)	2	$1.3M+

The final month is incomplete; plus signs mark minimum disclosed totals.

Are medical imaging AI investors looking beyond good algorithms?

Yes, medical imaging AI investors now have evidence of hospital use and reimbursement to examine alongside clinical test results.

Incepto Medical said in September 2026 that its platform reached more than 1,000 medical centers across ten countries and supported examinations for 6 million patients each year. Sirona Medical said in October 2026 that its platform handled more than 12 million primary imaging exams per year under contract. Both are company-reported operating measures. They tell us something about distribution but cannot establish profit or independently measured outcomes.

Cleerly secured Medicare contractor coverage for AI-assisted plaque analysis and later announced commercial insurer coverage. Subtle Medical works with scanners hospitals already own rather than requiring replacement equipment. These concrete routes to clinical use give investors something more useful than an impressive model demo alone. A company still needs to show whether hospitals will use the software, pay for it and keep it in their daily workflow.

So, what does medical imaging AI funding actually look like today?

Medical imaging AI is a substantial but uneven funding market, with many modest rounds and a much smaller group of companies raising the largest checks.

Our full-window research covers 172 deals and at least $2.8B. Detection & Diagnostic AI still leads, but reporting, measurements, pathology and image acquisition draw meaningful support too. Later rounds take most of the disclosed money even though Seed remains the busiest stage by deal count. Aidoc raised the most over the period and also closed the largest single round, $150M in April 2026.

The next test for imaging AI startups is routine clinical use. A product that works in a study still has to fit existing systems, win medical trust and find a buyer or reimbursement route. The funding figures show a market past its earliest experiments, although the biggest announcements remain far from representative of a normal startup.

The table below shows what we found.

Question	Answer
Are billion-dollar totals hiding much smaller checks?	Yes, medical imaging AI attracts substantial capital across many small financings. The median publicly disclosed round is $9.3M in our study. A giant announcement therefore does not describe a typical company's options.
Have nine-figure rounds become the ordinary deal?	No, such rounds remain rare even among funded imaging companies. Just 5 disclosed deals reached nine figures during the window. Those checks still account for an outsized part of the market.
Does the largest financing identify the leading company?	Here it does, because Aidoc leads on both measures. Aidoc raised $260M across 2 financings in our covered window. Its $150M round in April 2026 is also the largest single deal.
Are diagnostic tools crowding out all other products?	No, the funding market has developed several distinct clinical businesses. Imaging Workflow & Reporting attracted at least $435M during the window. Hospitals also pay for faster workflows, not just diagnostic predictions.
Are later rounds still available to imaging companies?	Yes, investors continue financing imaging AI well beyond early testing. Series C accounted for 19 deals in the covered period. Those financings support companies with longer clinical and commercial journeys.
Is startup creation still visible behind established names?	Yes, new companies still complete qualifying initial rounds of financing. First financings accounted for 34 deals in our research window. Most disclosed money nevertheless goes to businesses returning for more capital.
Can investors back products that never diagnose disease?	Absolutely, image enhancement and acquisition guidance attract serious venture capital. Image Reconstruction & Enhancement recorded $168M of disclosed funding. Improving scan efficiency can matter before any radiologist makes a diagnosis.
Has dental AI broken out of general radiology?	Yes, funded products now target routine dental scans and orthodontics. Videa's $40M Series B illustrates investor support for specialized workflows. Commercial distribution is the test, not a generic AI label.
Is the startup base truly dominated by newcomers?	No, many funded imaging AI businesses predate the current hype. The median company age at financing was 6 years. Clinical authorization and hospital sales usually reward a longer operating history.
Are Europe and America leading on identical measures?	No, Europe wins on transactions while North America leads on capital. Europe recorded 75 deals during our full coverage window. North American financings included a heavier concentration of large checks.
Does a strong month prove funding is accelerating?	No, one large deal can reshape a monthly fundraising total. January 2025 attracted $265M in our monthly figures. Such spikes demand context rather than extrapolation into permanent growth.